Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07527650 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

A Phase 2 study, sponsored by Hanmi Pharmaceutical Company Limited.

Recruiting
Registry status
Phase 2
Development phase
180
Enrollment target

NCT07527650: Recruiting Phase 2 study, sponsored by Hanmi Pharmaceutical Company Limited.

NCT07527650 is a Phase 2 study that is actively recruiting participants, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07527650, a Phase 2 study, is actively recruiting participants, sponsored by Hanmi Pharmaceutical Company Limited.

RECRUITING
Registry status
Phase 2
Development phase
180 participants
Enrollment target

Study Summary

This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.

Primary Outcome

Change in HbA1c (%) from randomization to Week 37.

Interventions

  • DRUG HM15275
  • DRUG Placebo of HM15275

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2026-05-18
Est. Completion 2027-10
Phase Phase 2

What NCT07527650 shows while recruiting

NCT07527650 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).

The record links to 0 conditions, and to 2 interventions - of which HM15275 is the first listed.

NCT07527650 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07527650 about?

NCT07527650 is a clinical study titled "Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus". This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.

What is the current status of trial NCT07527650?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2026-05-18. Estimated completion is 2027-10.

What interventions are being tested in trial NCT07527650?

The interventions under investigation include: HM15275 (DRUG), Placebo of HM15275 (DRUG).

Who is sponsoring clinical trial NCT07527650?

This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07527650's enrollment target sits among peer trials

180 365th of 2000 higher than 1,610 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07527650, the US trial registry maintained by the National Library of Medicine. NCT07527650 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.